Emerging molecular therapies of advanced thyroid cancer

Molecular Aspects of Medicine

Volumn 31, Issue 2, 2010, Pages 215-226

  Catalano, Maria Graziella ^a   Poli, Roberta ^a   Pugliese, Mariateresa ^a   Fortunati, Nicoletta ^b   Boccuzzi, Giuseppe ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Oncological Endocrinology   (Italy)

Author keywords

Anaplastic thyroid cancer; Epigenetic; Histone deacetylase inhibitors; Poorly differentiated thyroid cancer; Target therapy; Valproic acid

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; COMBRETASTATIN A4 PHOSPHATE; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MANUMYCIN; MONOCLONAL ANTIBODY; MOTESANIB; PACLITAXEL; PANOBINOSTAT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOTRANSFERASE INHIBITOR; PROTEASOME INHIBITOR; RADIOACTIVE IODINE; RETINOIC ACID; ROSIGLITAZONE; SORAFENIB; SUNITINIB; THALIDOMIDE DERIVATIVE; TROGLITAZONE; UNINDEXED DRUG; UNTRANSLATED RNA; VALPROIC ACID; VANDETANIB; VORINOSTAT;

ADVANCED CANCER; ANAPLASTIC CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL FUNCTION; CHROMATIN; CLINICAL TRIAL; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; EPILEPSY; GENE MUTATION; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR THERAPY; MOOD DISORDER; NONHUMAN; ONCOGENE RAS; PAPILLOMA; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; HUMANS; THYROID NEOPLASMS;

EID: 77951499047     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2010.02.006     Document Type: Review

References (101)

1. Ain K.B., Lee C., Williams K.D. Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 2007, 17:663-670.
2. Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009, 280:233-241.
3. Beauregard D.A., Thelwall P.E., Chaplin D.J., Hill S.A., Adams G.E., Brindle K.M. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer 1998, 77:1761-1767.
4. Blaheta R.A., Michaelis M., Driever P.H., Cinatl J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med. Res. Rev. 2005, 25:383-397.
5. Catalano M.G., Fortunati N., Pugliese M., Costantino L., Poli R., Bosco O., Boccuzzi G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 2005, 90:1383-1389.
6. Catalano M.G., Fortunati N., Pugliese M., Poli R., Bosco O., Mastrocola R., Aragno M., Boccuzzi G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 2006, 191:465-472.
7. Catalano M.G., Poli R., Pugliese M., Fortunati N., Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr. Relat. Cancer 2007, 14:839-845.
8. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19:189-195.
9. Chapman A., Keane P.E., Meldrum B.S., Simiand J., Verniers J.C. Mechanism of anticonvulsant action of valproate. Prog. Neurobiol. 1982, 19:315-359.
10. Ciampi R., Nikiforov Y.E. Alterations of the BRAF gene in thyroid tumors. Endocr. Pathol. 2005, 16:163-172.
11. Coelho S.M., Corbo R., Buescu A., Carvalho D.P., Vaisman M. Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J. Endocrinol. Invest. 2004, 27:334-339.
12. Cohen E.E., Rosen L.S., Vokes E.E., Kies M.S., Forastiere A.A., Worden F.P., Kane M.A., Sherman E., Kim S., Bycott P., Tortorici M., Shalinsky D.R., Liau K.F., Cohen R.B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 2008, 26:4708-4713.
13. Conticello C., Adamo L., Giuffrida R., Vicari L., Zeuner A., Eramo A., Anastasi G., Memeo L., Giuffrida D., Iannolo G., Gulisano M., De Maria R. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J. Clin. Endocrinol. Metab. 2007, 92:1938-1942.
14. Copland J.A., Marlow L.A., Williams S.F., Grebe S.K., Gumz M.L., Maples W.J., Silverman V.E., Smallridge R.C. Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases. Thyroid 2006, 16:1293-1302.
15. Dawson S.J., Conus N.M., Toner G.C., Raleigh J.M., Hicks R.J., McArthur G., Rischin D. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008, 19:547-552.
16. (-) symporter (NIS) research in the thyroid and beyond. Mol. Cell. Endocrinol. 2003, 213:59-70.
17. Dowlati A., Robertson K., Cooney M., Petros W.P., Stratford M., Jesberger J., Rafie N., Overmoyer B., Makkar V., Stambler B., Taylor A., Waas J., Lewin J.S., McCrae K.R., Remick S.C. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002, 62:3408-3416.
18. Duenas-Gonzalez A., Candelaria M., Perez-Plascencia C., Perez-Cardenas E., de la Cruz-Hernandez E., Herrera L.A. Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat. Rev. 2008, 34:206-222.
19. Dziba J.M., Marcinek R., Venkataraman G., Robinson J.A., Ain K.B. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002, 12:1063-1070.
20. Fagin J.A. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol. Endocrinol. 2002, 16:903-911.
21. Fassnacht M., Kreissl M.C., Weismann D., Allolio B. New targets and therapeutic approaches for endocrine malignancies. Pharmacol. Ther. 2009, 123:117-141.
22. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer. 2004, 4:143-153.
23. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
24. Foley D.L., Craig J.M., Morley R., Olsson C.A., Dwyer T., Smith K., Saffery R. Prospects for epigenetic epidemiology. Am. J. Epidemiol. 2009, 169:389-400.
25. - symporter and iodine uptake in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 2004, 89:1006-1009.
26. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Pérez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37:391-400.
27. Fröhlich E., Brossart P., Wahl R. Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:780-790.
28. Fuino L., Bali P., Wittmann S., Donapaty S., Guo F., Yamaguchi H., Wang H.G., Atadja P., Bhalla K. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2003, 2:971-984.
29. Galustian C., Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert. Opin. Pharmacother. 2009, 10:125-133.
30. Garcia-Rostan G., Camp R.L., Herrero A., Carcangiu M.L., Rimm D.L., Tallini G. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am. J. Pathol. 2001, 158:987-996.
31. Ghossein R. Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch. Pathol. Lab. Med. 2009, 133:683-691.
32. Görges R., Kahaly G., Müller-Brand J., Mäcke H., Roser H.W., Bockisch A. Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer. Thyroid 2001, 11:647-659.
33. Göttlicher M., Minucci S., Zhu P., Krämer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 17:6969-6978.
34. Grüning T., Tiepolt C., Zöphel K., Bredow J., Kropp J., Franke W.G. Retinoic acid for redifferentiation of thyroid cancer-does it hold its promise?. Eur. J. Endocrinol. 2003, 148:395-402.
35. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S.J., Flaherty K.T., Loevner L.A., O'Dwyer P.J., Brose M.S. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 2008, 26:4714-4719.
36. Haugen B.R., Larson L.L., Pugazhenthi U., Hays W.R., Klopper J.P., Kramer C.A., Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J. Clin. Endocrinol. Metab. 2004, 89:272-280.
37. Herbst R.S., Heymach J.V., O'Reilly M.S., Onn A., Ryan A.J. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert. Opin. Investig. Drugs 2007, 16:239-249.
38. Hoffmann S., Burchert A., Wunderlich A., Wang Y., Lingelbach S., Hofbauer L.C., Rothmund M., Zielke A. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine 2007, 31:105-113.
39. Imanishi R., Ohtsuru A., Iwamatsu M., Iioka T., Namba H., Seto S., Yano K., Yamashita S. A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy. J. Clin. Endocrinol. Metab. 2002, 87:4814-4821.
40. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1:287-299.
41. Karasarides M., Chiloeches A., Hayward R., Niculescu-Duvaz D., Scanlon I., Friedlos F., Ogilvie L., Hedley D., Martin J., Marshall C.J., Springer C.J., Marais R. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
42. Kebebew E., Peng M., Reiff E., Treseler P., Woeber K.A., Clark O.H., Greenspan F.S., Lindsay S., Duh Q.Y., Morita E. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006, 140:960-966.
43. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23:3923-3931.
44. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63:7291-7300.
45. Kim S., Prichard C.N., Younes M.N., Yazici Y.D., Jasser S.A., Bekele B.N., Myers J.N. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res. 2006, 12:600-607.
46. Kim D.W., Jo Y.S., Jung H.S., Chung H.K., Song J.H., Park K.C., Park S.H., Hwang J.H., Rha S.Y., Kweon G.R., Lee S.J., Jo K.W., Shong M. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 2006, 91:4070-4076.
47. Kim T.H., Yoo Y.H., Kang D.Y., Suh H., Park M.K., Park K.J., Kim S.H. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. Int. J. Oncol. 2009, 34:1353-1362.
48. (-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86:3430-3435.
49. Kitazono M., Bates S., Fok P., Fojo T., Blagosklonny M.V. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. Cancer Biol. Ther. 2002, 1:665-668.
50. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., Wakely P.E., Vasko V.V., Saji M., Rittenberry J., Wei L., Arbogast D., Collamore M., Wright J.J., Grever M., Shah M.H. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 2009, 27:1675-1684.
51. Kohlfuerst S., Igerc I., Gallowitsch H.J., Gomez I., Kresnik E., Matschnig S., Lind P. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?. Thyroid 2006, 16:1113-1119.
52. Kondo T., Asa S.L., Ezzat S. Epigenetic dysregulation in thyroid neoplasia. Endocrinol. Metab. Clin. North Am. 2008, 37:389-400.
53. Kondo T., Nakazawa T., Ma D., Niu D., Mochizuki K., Kawasaki T., Nakamura N., Yamane T., Kobayashi M., Katoh R. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab. Invest. 2009, 89:791-799.
54. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000, 289:1357-1360.
55. Lanzi C., Cassinelli G., Nicolini V., Zunino F. Targeting RET for thyroid cancer therapy. Biochem. Pharmacol. 2009, 77:297-309.
56. Liu Y.Y., Stokkel M.P., Pereira A.M., Corssmit E.P., Morreau H.A., Romijn J.A., Smit J.W. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur. J. Endocrinol. 2006, 154:525-531.
57. Liu Y.Y., Stokkel M.P., Morreau H.A., Pereira A.M., Romijn J.A., Smit J.W. Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clin. Endocrinol. (Oxf). 2008, 68:605-609.
58. Luong Q.T., O'Kelly J., Braunstein G.D., Hershman J.M., Koeffler H.P. Anti-tumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin. Cancer Res. 2006, 12:5570-5577.
59. Marchion D.C., Bicaku E., Daud A.I., Sullivan D.M., Munster P.N. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005, 65:3815-3822.
60. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S., Yoshida M. In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J. 2002, 21:6820-6831.
61. McEwan I.J. Nuclear receptors: one big family. Methods Mol. Biol. 2009, 505:3-18.
62. Miasaki F.Y., Vivaldi A., Ciampi R., Agate L., Collecchi P., Capodanno A., Pinchera A., Elisei R. Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment. J. Endocrinol. Invest. 2008, 31:724-730.
63. Mitsiades C.S., Poulaki V., McMullan C., Negri J., Fanourakis G., Goudopoulou A., Richon V.M., Marks P.A., Mitsiades N. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin. Cancer Res. 2005, 11:3958-3965.
64. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
65. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002, 13:3-16.
66. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W., Tallini G., Kroll T.G., Nikiforov Y.E. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003, 88:2318-2326.
67. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
68. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab. 2008, 93:1600-1608.
69. Noguchi H., Yamashita H., Murakami T., Hirai K., Noguchi Y., Maruta J., Yokoi T., Noguchi S. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr. J. 2009, 56:245-249.
70. Patel K.N., Shaha A.R. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006, 13:119-128.
71. Pennell N.A., Daniels G.H., Haddad R.I., Ross D.S., Evans T., Wirth L.J., Fidias P.H., Temel J.S., Gurubhagavatula S., Heist R.S., Clark J.R., Lynch T.J. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18:317-323.
72. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 2001, 276:36734-36741.
73. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Thangue N.B., Brown R. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2003, 2:721-728.
74. Prichard C.N., Kim S., Yazici Y.D., Doan D.D., Jasser S.A., Mandal M., Myers J.N. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007, 117:674-679.
75. Prince H.M., Bishton M.J., Johnstone R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009, 5:601-612.
76. Provenzano M.J., Fitzgerald M.P., Krager K., Domann F.E. Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-aza-dC). Otolaryngol. Head Neck Surg. 2007, 137:722-728.
77. Pugliese M., Gargantini E., Poli R., Fortunati N., Catalano M.G., Boccuzzi G. Panobinostat (LBH589), a novel deacetylase inhibitor, targets microtubules in undifferentiated thyroid cancer cells. J. Clin. Invest. 2009, 32:12.
78. Sakorafas, G.H., Sampanis, D., Safioleas, M., 2009. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg. Oncol. (Epub ahead of print).
79. Schweppe R.E., Kerege A.A., Sharma V., Poczobutt J.M., Gutierrez-Hartmann A., Grzywa R.L., Haugen B.R. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid 2009, 19:825-835.
80. Shen W.T., Wong T.S., Chung W.Y., Wong M.G., Kebebew E., Duh Q.Y., Clark O.H. Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 2005, 138:979-984.
81. Sherman S.I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 2009, 94:1493-1499.
82. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., Licitra L., Eschenberg M.J., Sun Y.N., Juan T., Stepan D.E., Schlumberger M.J. Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 2008, 359:31-42. Motesanib Thyroid Cancer Study Group.
83. Short S.C., Suovuori A., Cook G., Vivian G., Harmer C. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin. Oncol. 2004, 16:569-574.
84. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 2009, 16:17-44.
85. Tepmongkol S., Keelawat S., Honsawek S., Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008, 18:697-704.
86. Trovisco V., Vieira de Castro I., Soares P., Máximo V., Silva P., Magalhães J., Abrosimov A., Guiu X.M., Sobrinho-Simões M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J. Pathol. 2004, 202:247-251.
87. Tzvetov G., Hirsch D., Shraga-Slutzky I., Weinstein R., Manistersky Y., Kalmanovich R., Mordechai L., Grozinsky-Glasberg S., Singer J., Sulkes J., Shimon I., Benbassat C. Well differentiated thyroid carcinoma: comparison of microscopic and macroscopic disease. Thyroid 2009, 19:487-494.
88. Ugolini C., Giannini R., Lupi C., Salvatore G., Miccoli P., Proietti A., Elisei R., Santoro M., Basolo F. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007, 17:381-388.
89. Van Nostrand D., Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol. Metab. Clin. North Am. 2007, 36:807-822. vii-viii.
90. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62:5749-5754.
91. Widakowich C., de Castro G., de Azambuja E., Dinh P., Awada A. Side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007, 12:1443-1455.
92. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A. BAY 43-9006 exhibits broad spectrum oral anti-tumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
93. Woyach J.A., Kloos R.T., Ringel M.D., Arbogast D., Collamore M., Zwiebel J.A., Grever M., Villalona-Calero M., Shah M.H. Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J. Clin. Endocrinol. Metab. 2009, 94:164-170.
94. Wreesmann V.B., Singh B. Clinical impact of molecular analysis on thyroid cancer management. Surg. Oncol. Clin. N. Am. 2008, 17:1-35.
95. Xiao X., Ning L., Chen H. Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol. Cancer Ther. 2009, 8:350-356.
96. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr. Rev. 2007, 28:742-762.
97. Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology 2007, 148:948-953.
98. Yeung S.C., She M., Yang H., Pan J., Sun L., Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 2007, 92:2902-2909.
99. Zhang K., Dent S.Y. Histone modifying enzymes and cancer: going beyond histones. J. Cell Biochem. 2005, 96:1137-1148.
100. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22:1168-1179.
101. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 2003, 120:71-77.